Gut 2010;59:A77-A78; doi:10.1136/gut.2009.209072e
Copyright © 2010 by BMJ Publishing Group Ltd.

Liver I posters

PTU-071 Frequency and outcomes associated with rapid viral response in individuals on pegylated interferon and ribavirin therapy

J M Tait, D Knight, J F Dillon

Department of Gastroenterology, Ninewells Hospital, Dundee, Scotland, UK

Introduction: Studies have shown that attaining a rapid viral response (RVR) (PCR negative after 4 weeks of interferon and ribavirin therapy) is emerging as a robust predictor of sustained viral response (SVR) to treatment. We started routinely measuring HCV PCR after 4 weeks of treatment in April 2007. The aim of this study was to evaluate the frequency and outcomes associated with RVR in clinical practice.

Methods: A prospective study was carried out on all individuals who had received interferon and ribavirin therapy in our centre between April 2007 and November 2009.

Results: A total of 164 individuals were included in the study. 111 (67.7%) were male. The age range was 19 to 77 with a mean of 43.8 years. 67 (40.8%) were genotype 1, 7 (4.2%) genotype 2, 88 (53.6%) genotype 3, and 2 (1.2%) genotype 4.

At end week 4, 80/164 (48.7%) had a RVR, of these 22% were genotype 1/4 and 67.7% were 2/3. Of the individuals who did not achieve a RVR, 49 (29.9%) had more than a 2-log drop in viral load, 28 (17%) had less than a 2-log drop and 7 (4.2%) stopped treatment before 4 weeks. 36 individuals are still in treatment. In 128 cases where treatment has ended 75% (96/128) completed treatment.

The following analysis focuses on the 96 individuals who are 6 months post treatment. Of the 39 had achieved an RVR (6 genotype 1/4. 33 genotype 2/3), three stopped treatment early (between 4 and 12 weeks) and 35 (97.2%) who subsequently completed treatment achieved a SVR. 21 (84%) who achieved more than a 2-log drop at 4 weeks and completed treatment had SVR and 3 (42.8%) who had less than a 2-log drop had SVR (Abstract 071).


Conclusion: This study shows that 48.7% of individuals achieved a RVR. The frequency of RVR was significantly altered by genotype. This study confirms that the result of viral load at 4 weeks is very predictive of an SVR if individuals adhere to treatment, with 97.2% of individuals with RVR who completed treatment achieving a SVR. The numbers in this study are small however the results can be used to motivate individuals with RVR or more than a 2 log drop in viral load at 4 weeks to complete their full course of treatment.

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.